

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – September 8, 2021 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Markita Broyles –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://zoom.us/webinar/register/WN_SdjzD5WzQlagkk8OsF1E2g

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 956 8429 1722

Passcode: 97508217

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms need to be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA. Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Items – Approval of DUR Board Meeting Minutes – See Appendix A

- A. **Action Item** – June 9, 2021 DUR Board Meeting Minutes – Vote
- B. June 9, 2021 DUR Board Recommendations Memorandum
- C. **Action Item** – July 14, 2021 DUR Board Meeting Minutes – Vote
- D. July 14, 2021 DUR Board Recommendations Memorandum

Items to be presented by Dr. Ha, Dr. Travers, Dr. Muchmore, Chairman:

4. Update on the Medication Coverage Authorization Unit/Pediatric Antipsychotic Monitoring Program Update – See Appendix B

- A. Pharmacy Helpdesk Activity for July 2021
- B. Medication Coverage Activity for July 2021
- C. Pharmacy Helpdesk Activity for August 2021
- D. Medication Coverage Activity for August 2021
- E. Pediatric Antipsychotic Monitoring Program Update

Items to be presented by Dr. Smith, Dr. Muchmore, Chairman:

5. Annual Review of the Medication Therapy Management (MTM) Program – See Appendix C

- A. Background
- B. Workflow
- C. Results
- D. Case Study
- E. Summary

Items to be presented by Dr. Nawaz, Dr. Wilson, Dr. Ha, Dr. Chandler, Dr. Muchmore, Chairman:

6. Action Items – Approval of July 2021 DUR Board Recommendations – See Appendix D

- A. **Action Item** – Vote to Prior Authorize Lybalvi™ (Olanzapine/Samidorphan)
 - i. Market News and Updates
 - ii. Lybalvi™ (Olanzapine/Samidorphan) Product Summary
 - iii. College of Pharmacy Recommendations
- B. **Action Item** – Vote to Prior Authorize Azstarys™ (Serdexmethylphenidate/Dexmethylphenidate), Qelbree™ (Viloxazine), and Xywav® (Calcium/Magnesium/Potassium/Sodium Oxybates)
 - i. Market News and Updates
 - ii. Product Summaries
 - iii. College of Pharmacy Recommendations
- C. **Action Item** – Vote to Prior Authorize Helidac® Therapy (Bismuth Subsalicylate/Metronidazole/Tetracycline Dose Pack) and Pylera® (Bismuth Subcitrate Potassium/Metronidazole/Tetracycline Capsule)
 - i. Market News and Updates
 - ii. *Helicobacter Pylori* (*H. Pylori*) Product Summaries
 - iii. Cost Comparison: *H. Pylori* Regimens
 - iv. College of Pharmacy Recommendations
- D. **Action Item** – Vote to Prior Authorize Alkindi® Sprinkle (Hydrocortisone Oral Granule), Eysuvis® (Loteprednol 0.25% Ophthalmic Suspension), Gimoti® (Metoclopramide Nasal Spray), Nextstellis® (Drospirenone/Estetrol), Ozobax™ (Baclofen 5mg/mL Oral Solution), Phexxi® (Lactic Acid/Citric Acid/Potassium Bitartrate Vaginal Gel), RediTrex™ (Methotrexate Injection), Reltone™ (Ursodiol Capsule), and Thyquidity™ (Levothyroxine Oral Solution)
 - i. Introduction
 - ii. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Qdolo™ (Tramadol 5mg/mL Oral Solution) – See Appendix E

- A. Market News and Updates
- B. Qdolo™ (Tramadol 5mg/mL Oral Solution) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Impeklo® (Clobetasol Propionate 0.05% Lotion) – See Appendix F

- A. Market News and Updates
- B. Impeklo® (Clobetasol Propionate 0.05% Lotion) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

9. Action Item – Vote to Update the Approval Criteria for the Ophthalmic Anti-Inflammatory Products – See Appendix G

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Nulibry™ (Fosdenopterin) – See Appendix H

- A. Market News and Updates
- B. Nulibry™ (Fosdenopterin) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Danyelza® (Naxitamab-gqgk) and Truseltiq™ (Infigratinib) – See Appendix I

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Feraheme® (Ferumoxytol), Injectafer® (Ferric Carboxymaltose), and Monoferric® (Ferric Derisomaltose) – See Appendix J

- A. Market News and Updates
- B. Product Summaries
- C. Cost Comparison
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

13. Action Item – Annual Review of Synagis® (Palivizumab) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Synagis® (Palivizumab)
- C. Prior Authorization of Synagis® (Palivizumab)
- D. Respiratory Syncytial Virus (RSV) Season Comparison
- E. Market News and Updates
- F. Oklahoma Updates
- G. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. Action Item – Annual Review of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of CFTR Modulators
- C. Prior Authorization of CFTR Modulators
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of CFTR Modulators

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

15. Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Herceptin® (Trastuzumab) and Margenza® (Margetuximab-cmkb) – See Appendix M

- A. Introduction

- B. Current Prior Authorization Criteria
- C. Utilization of Breast Cancer Medications
- D. Prior Authorization of Breast Cancer Medications
- E. Market News and Updates
- F. Margenza® (Margetuximab-cmkb) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

16. Annual Review of Prostate Cancer Medications and 30-Day Notice to Prior Authorize Orgovyx™ (Relugolix) – See Appendix N

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Prostate Cancer Medications
- D. Prior Authorization of Prostate Cancer Medications
- E. Market News and Updates
- F. Orgovyx™ (Relugolix) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Prostate Cancer Medications

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

17. Annual Review of Cystadrops® (Cysteamine 0.37% Ophthalmic Solution) and Cystaran® (Cysteamine 0.44% Ophthalmic Solution) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Cystadrops® and Cystaran®
- C. Prior Authorization of Cystadrops® and Cystaran®
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

- A. Hepatitis C Medications
- B. Ovarian Cancer Medications
- C. Spinal Muscular Atrophy (SMA) Medications
- D. Targeted Immunomodulator Agents

**Future product and class reviews subject to change.*

20. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.